MIRA INFORM REPORT

 

 

Report Date :

01.02.2014

 

IDENTIFICATION DETAILS

 

Name :

ALLIANCE PHARMACEUTICALS (PVT) LTD (APPL)

 

 

Registered Office :

112-A Hayatabad Industrial Estate, Jamrud Road, Peshawar

 

 

Country :

Pakistan

 

 

Financials (as on) :

30.06.2012

 

 

Date of Incorporation :

08.01.2002

 

 

Com. Reg. No.:

0043229

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacturing of Pharmaceutical Products.

 

 

No. of Employees :

90

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 01, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 


 

PAKISTAN - ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is under 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in 2012. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in fiscal year 2012, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3% per year from 2008 to 2012. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.

 

Source : CIA

 


 

company Name

 

ALLIANCE PHARMACEUTICALS (PVT) LTD (APPL)

 

 

GENERAL INFORMATION

 

Business Name

Business Name:

Alliance Pharmaceuticals (Pvt.) Ltd. (APPL)

 

Inquiry Name:

Alliance Chem International

Address

Registered Address:

112-A Hayatabad Industrial Estate, Jamrud Road, Peshawar

Telephone

(+92) (91) 5891308

Fax

(+92) (91) 5830268

Email

alliancepharmo@hotmail.com

Website

None

Business activities

Manufacturing of Pharmaceutical

 

Registry Details

 

CRO Registration Number

0043229

Date of Registration

January 08, 2002

           

Other registry & certification details:

Current Legal Form

Private Limited Company

National Tax Registration Number

2250492-3

Date of Registration

February 23, 2005

GST Registration Number

0501300002228

Date of Registration

February 08, 2008

Chamber of Commerce & Industry

Peshawar Chamber of Commerce & Industries

ISO Certification

Undetermined

Other certifications

Undetermined

 

Capital

Type

No. of Shares

Par Value

Total Value

Authorized

150,000

100

15,000,000

Issued, Subscribed & Paid-Up

150,000

100

15,000,000

 

History

Who started

Mr. Aziz Ahmed

When started

January 15, 2002

Change in management

None

Year of change

N/A

Change in legal status

None

Year of change

N/A

Change in business name

None

Year of change

N/A

 

 

PRINCIPALS (SPONSORS)

 

Name

Number of Shares

Nationality

Appointment Date (Last)

Mr. Jamal Salim

       33,000

Pakistani

31 Oct 2010

Mr. Muhammad Arif  Sidique

       30,000

Pakistani

31 Oct 2010

Mr. Aziz Ahmad

        25,500

Pakistani

31 Oct 2010

Mr. Abid Salam

        24,750

Pakistani

31 Oct 2010

Other share holder

 

 

Ms.Aisha Rahim

        24,750

 

Mr.Hamid Tariq

12,000

 

Total

       150,000

 

 

 

KEY MANAGEMENT

 

Name

 

Position in organization

Qualification

Years in employment

Mr. Aziz Ahmad

CEO

Undetermined

Undetermined

Mr. Shaheen Ullah

Finance Manager

    MBA

 08 Years

 

 

Statutory offices

Name of service provider

Statutory Auditors

M/s. Sajjad Hasnain & Co

Chartered Accountants

Legal Advisory Services

 Mr.Muneer Awan

 

 

BANKERS

 

Bank name

Approved financing limits PKR

Bank Of Khyber

40,000,000

 


 

DETAILS OF BUSINESS ACTIVITIES

 

The core business focus of APPL is manufacturing of different Pharmaceutical products.

                                    Products:                    

Analgesics, Antipyretics, Nsaids, Antigout, And Antirheumatics (Category - 2)

ACLOFEN

 

APROLEX

 

·                    

ARAAM

 

·                    

ARAAM SR

 

·                    

AZIDOL

 

·                    

CHILPOL

 

·                    

CHILPOL CF

 

·                    

CHILPOL EXTRA

 

·                    

CHILPOL TOTAL SUSPENTION

 

·                    

DFINEP

 

·                    

FLUSAID

 

·                    

IBUPED

 

·                    

MAPROLEX

 

·                    

MEPEX

 

·                    

PAINTON

 

·                    

PAINTON FORTE

 


Anti-Allergics (Antihistamines) And Drugs Used In Anaphylaxis (Category - 3)

·                    

FEXOFAX

 

·                    

LETIRIX

 

·                    

LORGY

 

·                    

ONE-BEST

 


Anti-Infective Drugs (Category - 6)

·                    

A-VID

 

·                    

ABCLOR

 

·                    

ABIDINE

 

·                    

ABIDOX

 

·                    

ABIFIX

 

·                    

ABIREX

 

·                    

AGAT

 

·                    

AGEMIX

 

·                    

ALIPRO

 

·                    

ALITOX

 

·                    

ALOVIC

 

·                    

APODOX

 

·                    

ARTITAR

 

·                    

ARULID

 

·                    

AZIZOX

 

·                    

BENTIL

 

·                    

EIPTRAN

 

·                    

EIPTRAN FORTE

 

·                    

KETOOZ

 

·                    

METGYL

 

·                    

MYCOVAG

 

·                    

NOROXO

 

·                    

RITEK

 

·                    

ROCEXON

 


Drugs Affecting The Blood (Category - 10)

·                    

CLOPLAD

 

·                    

IROCOM

 

·                    

IROFOLIC

 

·                    

MECO

 


Cardiovascular Drugs (Category - 12)

·                    

CADILOL

 

·                    

EMEB

 

·                    

ENETEC

 

·                    

MEVODIP

 

·                    

SOZAAR

 

·                    

ZENOPRIL

 

 

 


Gastrointestinal Drugs (Category - 17)

·                    

AFOMIT

 

·                    

AIXYLIX

 

·                    

AMOP

 

·                    

EPIM

 

·                    

MOLIUM

 

·                    

OSMALAC

 

·                    

PIROGAN

 

·                    

SPAS-G

 

·                    

SUCRALIF

 

·                    

T-RSIL

 

·                    

TIMIT

 

·                    

ZOMTIC

 


Hormones And Other Endocrine Drugs And Contraceptives (Category - 18)

·                    

GLIMRYL

 

·                    

UMEED

 

 

 


Obstetrics And Gynecological Preparations (Category - 22)

PRAXOL

 

 

 

 


Psychotherapeutic Drugs (Category - 24)

·                    

CITPRIM

 

·                    

E-CITPRIM

 

·                    

PARTIN

 

 


Drugs Acting On The Respiratory Tract (Category - 25)

·                    

AKTOFEN

 

·                    

ALMUNOL

 

·                    

ALUKAST

 

·                    

BAMBU

 

·                    

CHILCOL

 

·                    

CHILMINIC

 

·                    

COLEN

 

·                    

VINBULIN

 


Hospital Fluids (Category - 26)

AROSAL F

 

 

 

 


Vitamins, Minerals, Tonics, And Other Susbstances (Category - 27)

·                    

ALBONE D

 

·                    

ALLIFER

 

·                    

AUCAIN

 

·                    

FOLIMIC

 

·                    

MAX-V

 

·                    

PIZOGAR

 

 

 

 

 

Purchases (Incl. Imports)

Imports from

Indian

Importing terms

L/C

Local

All over Pakistan

Local buying terms

Cash and Credit of 30-45 days

 

 

Sales (Incl. Exports)

Exports to

Afghanistan

Exporting terms

N/A

Local (%)

Undetermined /not disclosed

Local selling terms

Cash and Credit of 45-60 Days

 

 

NUMBER OF EMPLOYEES

 

Nature of employment

Current Year

Previous Year

All Staff

90

90

Total

90

90

 

 

BUSINESS FACILITIES

 

Head office Address

Owned / Rented

Area (approx)

112-A Hayatabad Industrial Estate Jamrud Road Peshawar

Leased

None Disclosed

Factory Address

Owned / Rented

Area (approx)

112-A Hayatabad Industrial Estate Jamrud Road Peshawar

Leased

None Disclosed

 

 

MARKET REPUTATION

 

 We contacted a customer and a supplier of APPL to get a feedback about its products and sponsors. All the feedback was found Satisfactory and no disputes or untoward events including complaints about quality of products were reported/ identified during inquiry.

 

 

DETAILS OF RELATED BUSINESSES

 

Business Name

City

Line of Business

Percentile of Shareholding

N/A

 

 

BUSINESS PERFORMANCE

 

Particulars

30-Jun-12

30-Jun-11

 % Change

 

 

 

 

Current assets

         16,901,438

        14,112,613

        19.76

Current liabilities

               28,612

          3,274,091

       (99.13)

Working capital

          16,872,826

        10,838,522

        55.67

 

 

 

 

Non-current assets

         12,791,977

        13,813,269

        (7.39)

Long term liabilities

                     -  

                    -  

#DIV/0!

Net worth

          29,664,803

        24,651,791

        20.34

 

 

 

 

Turnover

          72,194,666

        71,865,965

          0.46

Gross Profit

           9,553,097

          9,364,100

          2.02

EBIT

           5,029,666

          4,965,012

          1.30

Profit / (Loss) before tax

           5,029,666

          4,965,012

          1.30

Financial Cost

               16,654

            146,396

       (88.62)

Profit / (Loss) after tax

            5,029,666

          4,818,616

           4.38

 

 

 

 

Creditors

               28,612

          3,274,091

      (99.13)

Deferred Cost

              671,780

            646,670

           3.88

Cash & bank balances

              771,397

            610,627

         26.33

Advanced,Deposit& Prepayments

           3,491,268

          2,754,170

         26.76

Growth trend

 

 

 

Sales growth (%)

0.46%

 

 

Gross profit growth (%)

2.02%

 

 

 

 

 

 

Solvency

 

 

 

Current ratio

               590.71

                 4.31

 

Quick ratio

               172.46

                 1.23

 

Total liabilities to net worth ratio (%)

                  0.10

                13.28

 

 

 

 

 

Profitability

 

 

 

Return on sales (%)

                  6.97

                 6.71

 

Return on net worth (%)

                 16.95

                19.55

 

 

 

 

 

 

 

INTERVIEW & REPORTER COMMENTS

 

Contact person

Mr.Shaheen Ullah

Position

Finance Manager

Contact Person Comments

Mr. Shaheen Ullah confirmed business operations and business information and provided financial information.    

Analyst’s Observations/ comments

i)                     The office comprised of fourteen air-conditioned rooms, with nine computers and average office furniture.

ii)                   Sixty to Seventy employees were present in the office premises at the time of physical visit.

iii)                  Sample of different Pharmaceutical Products were observed at site. 

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.48

UK Pound

1

Rs.102.95

Euro

1

Rs.84.60

 

 

INFORMATION DETAILS

 

Report Prepared by :

NIT

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.